

# AlÃ- Duarte-GarcÃ-a

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8018663/publications.pdf>

Version: 2024-02-01

52  
papers

1,641  
citations

393982

19  
h-index

315357

38  
g-index

52  
all docs

52  
docs citations

52  
times ranked

2398  
citing authors

#	ARTICLE	IF	CITATIONS
1	A Rush to Judgment? Rapid Reporting and Dissemination of Results and Its Consequences Regarding the Use of Hydroxychloroquine for COVID-19. <i>Annals of Internal Medicine</i> , 2020, 172, 819-821.	2.0	177
2	The Epidemiology of Antiphospholipid Syndrome: A Population-Based Study. <i>Arthritis and Rheumatology</i> , 2019, 71, 1545-1552.	2.9	172
3	Associations of baseline use of biologic or targeted synthetic DMARDs with COVID-19 severity in rheumatoid arthritis: Results from the COVID-19 Global Rheumatology Alliance physician registry. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 1137-1146.	0.5	151
4	<scp>SARS</scp>â€“<scp>CoV</scp>â€“2 Infection and <scp>COVID</scp>â€“19 Outcomes in Rheumatic Diseases: A Systematic Literature Review and Meta-Analysis. <i>Arthritis and Rheumatology</i> , 2022, 74, 766-775.	2.9	117
5	Antiphospholipid Syndrome. <i>Journal of the American College of Cardiology</i> , 2017, 69, 2317-2330.	1.2	109
6	Association Between Tumor Necrosis Factor Inhibitors and the Risk of Hospitalization or Death Among Patients With Immune-Mediated Inflammatory Disease and COVID-19. <i>JAMA Network Open</i> , 2021, 4, e2129639.	2.8	86
7	16th International Congress on Antiphospholipid Antibodies Task Force Report on Antiphospholipid Syndrome Treatment Trends. <i>Lupus</i> , 2020, 29, 1571-1593.	0.8	80
8	Swinging the pendulum: lessons learned from public discourse concerning hydroxychloroquine and COVID-19. <i>Expert Review of Clinical Immunology</i> , 2020, 16, 659-666.	1.3	57
9	Antirheumatic Disease Therapies for the Treatment of COVID-19: A Systematic Review and Meta-Analysis. <i>Arthritis and Rheumatology</i> , 2021, 73, 36-47.	2.9	52
10	Effect of Therapy on Radiographic Progression in Axial Spondyloarthritis: A Systematic Review and Meta-Analysis. <i>Arthritis and Rheumatology</i> , 2020, 72, 733-749.	2.9	51
11	Characteristics associated with poor COVID-19 outcomes in individuals with systemic lupus erythematosus: data from the COVID-19 Global Rheumatology Alliance. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, 970-978.	0.5	49
12	Epidemiology of Antiphospholipid Syndrome in the General Population. <i>Current Rheumatology Reports</i> , 2021, 23, 85.	2.1	49
13	Endorsement of the 66/68 Joint Count for the Measurement of Musculoskeletal Disease Activity: OMERACT 2018 Psoriatic Arthritis Workshop Report. <i>Journal of Rheumatology</i> , 2019, 46, 996-1005.	1.0	36
14	<i>Festina lente</i>: hydroxychloroquine, COVID-19 and the role of the rheumatologist. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 734-736.	0.5	35
15	Baricitinib for relapsing giant cell arteritis: a prospective open-label 52-week pilot study. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, 861-867.	0.5	35
16	The Evidence Basis for the American College of Rheumatology Practice Guidelines. <i>JAMA Internal Medicine</i> , 2018, 178, 146.	2.6	33
17	COVID-19 vaccine perceptions and uptake: results from the COVID-19 Global Rheumatology Alliance Vaccine Survey. <i>Lancet Rheumatology</i> , The, 2022, 4, e237-e240.	2.2	30
18	Diagnostic Delay in Psoriatic Arthritis: A Population-based Study. <i>Journal of Rheumatology</i> , 2021, 48, 1410-1416.	1.0	25

#	ARTICLE	IF	CITATIONS
19	The Epidemiology of Psoriatic Arthritis Over Five Decades: A Population-Based Study. <i>Arthritis and Rheumatology</i> , 2021, 73, 1878-1885.	2.9	25
20	Rising incidence and prevalence of systemic lupus erythematosus: a population-based study over four decades. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, 1260-1266.	0.5	23
21	Industry Payments to Practicing US Rheumatologists, 2014-2019. <i>Arthritis and Rheumatology</i> , 2021, 73, 2138-2144.	2.9	22
22	Disease activity, autoantibodies, and inflammatory molecules in serum and cerebrospinal fluid of patients with Systemic Lupus Erythematosus and Cognitive Dysfunction. <i>PLoS ONE</i> , 2018, 13, e0196487.	1.1	21
23	Predictors of incident proteinuria among patients with SLE. <i>Lupus Science and Medicine</i> , 2017, 4, e000200.	1.1	19
24	Acute respiratory viral adverse events during use of antirheumatic disease therapies: A scoping review. <i>Seminars in Arthritis and Rheumatism</i> , 2020, 50, 1191-1201.	1.6	19
25	Antigen Specific Humoral and Cellular Immunity Following SARS-CoV-2 Vaccination in ANCA-Associated Vasculitis Patients Receiving B-Cell Depleting Therapy. <i>Frontiers in Immunology</i> , 2022, 13, 834981.	2.2	19
26	Effect of omega-3 fatty acids on systemic lupus erythematosus disease activity: A systematic review and meta-analysis. <i>Autoimmunity Reviews</i> , 2020, 19, 102688.	2.5	17
27	Disease progression of Takayasu arteritis in two patients treated with tocilizumab. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, e21-e21.	0.5	15
28	Effect of statin use on the risk of rheumatoid arthritis: A systematic review and meta-analysis. <i>Seminars in Arthritis and Rheumatism</i> , 2020, 50, 1348-1356.	1.6	13
29	Population-based incidence and time to classification of systemic lupus erythematosus by three different classification criteria: a Lupus Midwest Network (LUMEN) study. <i>Rheumatology</i> , 2022, 61, 2424-2431.	0.9	12
30	Measuring Outcomes in Axial Spondyloarthritis. <i>Arthritis Care and Research</i> , 2020, 72, 47-71.	1.5	11
31	Association Between Payments by Pharmaceutical Manufacturers and Prescribing Behavior in Rheumatology. <i>Mayo Clinic Proceedings</i> , 2022, 97, 250-260.	1.4	10
32	The protective effect of rheumatic disease agents in COVID-19. <i>Best Practice and Research in Clinical Rheumatology</i> , 2021, 35, 101659.	1.4	9
33	COVID-19 in Pregnant Women With Rheumatic Disease: Data From the COVID-19 Global Rheumatology Alliance. <i>Journal of Rheumatology</i> , 2022, 49, 110-114.	1.0	9
34	Older Drugs With Limited Trial Evidence: Are They Worth the Expense? The Case of Repository Corticotropin Marketed as H.P. Acthar Gel. <i>Annals of Internal Medicine</i> , 2019, 170, 791.	2.0	9
35	Treatment of thrombotic antiphospholipid syndrome in adults and children. <i>Current Opinion in Rheumatology</i> , 2020, 32, 215-227.	2.0	8
36	Systematic Appraisal of the American College of Rheumatology Clinical Practice Guidelines. <i>ACR Open Rheumatology</i> , 2019, 1, 188-193.	0.9	7

#	ARTICLE	IF	CITATIONS
37	Epidemiology of <sc>Childhoodâ€œOnset</sc> Systemic Lupus Erythematosus: A <sc>Populationâ€œBased</sc> Study. Arthritis Care and Research, 2022, 74, 728-732.	1.5	7
38	Time to transition from psoriasis to psoriatic arthritis: A population-based study. Seminars in Arthritis and Rheumatism, 2022, 52, 151949.	1.6	6
39	Risk of hydroxychloroquine retinopathy in the community. Rheumatology, 2022, 61, 3172-3179.	0.9	5
40	Older Drugs With Limited Trial Evidence: Are They Worth the Expense?. Annals of Internal Medicine, 2019, 171, 602.	2.0	3
41	Soluble LILRA3 is aberrantly expressed in antiphospholipid syndrome (APS) and is a potential marker of thrombotic APS. Rheumatology, 2022, 61, 4962-4974.	0.9	3
42	Response to: â€œCorrespondence on â€œ<i>Festina lente</i>: hydroxychloroquine, COVID-19and the role of the rheumatologistâ€œ™ by Graef<i>et al</i>â€œ™ by Lo<i>et al</i>. Annals of the Rheumatic Diseases, 2022, 81, e164-e164.	0.5	2
43	Striatal Encephalitis: Potential Inflammatory Vasculopathy in Systemic Lupus Erythematosus. Canadian Journal of Neurological Sciences, 2021, 48, 415-416.	0.3	2
44	28-Year-Old Woman With Chronic Kidney Disease, Fatigue, and Polyarthralgias. Mayo Clinic Proceedings, 2021, 96, 231-236.	1.4	1
45	Reply. Arthritis and Rheumatology, 2019, 71, 1769-1770.	2.9	0
46	Reply. Arthritis and Rheumatology, 2020, 72, 2164-2165.	2.9	0
47	Reply. Arthritis and Rheumatology, 2020, 72, 1776-1776.	2.9	0
48	28-Year-Old Man With Recurrent Vertigo, Syncope, and Progressive Memory Impairment. Mayo Clinic Proceedings, 2021, 96, 1309-1314.	1.4	0
49	Reply. Arthritis and Rheumatology, 2021, 73, 1767-1768.	2.9	0
50	Characteristics of Hydroxychloroquine Dispensing in the United States, January to May 2020. Journal of General Internal Medicine, 2021, , 1.	1.3	0
51	75-Year-Old Man With Fever and Malaise. Mayo Clinic Proceedings, 2021, 96, 2905-2910.	1.4	0
52	Industry involvement in rheumatology consensus-based recommendations: a systematic review. Lancet Rheumatology, The, 2022, 4, e145-e152.	2.2	0